Non-Executive Chairman
life sciencess
Great Harvest Bread?Co
American Samoa
prior to that at Elan/Perrigo, where she led the development of ELND005, an amyloid targeting small molecule being developed for neuropsychiatric symptoms in Alzheimer’s disease and in Down syndrome. Previously, Dr. Abushakra was Vice President of Clinical Development at Elan Corporation and Allergan, where she led several early and late stage central nervous system and pain clinical programs, including supplemental biologics license application (sBLA) filings for Botox® in spasticity and migraine. Dr. Abushakra has extensive clinical and regulatory experience
prior to that at Elan/Perrigo, where she led the development of ELND005, an amyloid targeting small molecule being developed for neuropsychiatric symptoms in Alzheimer’s disease and in Down syndrome. Previously, Dr. Abushakra was Vice President of Clinical Development at Elan Corporation and Allergan, where she led several early and late stage central nervous system and pain clinical programs, including supplemental biologics license application (sBLA) filings for Botox® in spasticity and migraine. Dr. Abushakra has extensive clinical and regulatory experience